ValiRx PLC

VAL

Company Profile

  • Business description

    ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.

  • Contact

    D6 Thane Road
    MediCity Nottingham
    NottinghamNG90 6BH
    GBR

    T: +44 1157840026

    E: [email protected]

    https://www.valirx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    11

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,052.7080.40-0.99%
CAC 407,672.77186.06-2.37%
DAX 4021,936.44454.40-2.03%
Dow JONES (US)42,225.32235.360.56%
FTSE 1008,485.23123.25-1.43%
HKSE22,849.81352.72-1.52%
NASDAQ17,601.05151.160.87%
Nikkei 22534,735.93989.94-2.77%
NZX 50 Index12,338.5718.380.15%
S&P 5005,670.9737.900.67%
S&P/ASX 2007,859.7074.80-0.94%
SSE Composite Index3,342.018.12-0.24%

Market Movers